News

Biologics to watch in 2013
Enlarge image

OutlookEUUK

Biologics to watch in 2013

02.01.2013 - At the beginning of the new year, 29 monoclonal antibody (mAbs) drugs are in Phase III clinical development.

While around 350 therapeutic mAbs are currently in clinical development globally, only 28 had entered active Phase 2/3 or Phase 3 studies as of January 2013, according to MABS. Additionally one mAb mixture was under evaluation in Phase III. Historically, mAbs that target antigens relevant to cancer have comprised approximately 50% of the mAb clinical pipeline, but in 2013 the picture has changed: 66% or 19 of the antibodies to watch in 2013 are for non-cancer indications.

The non-cancer mAbs include alirocumab (Regeneron; Sanofi, hypercholesterinemia); AMG 145 (Amgen, hypercholesterinemia), epratuzumab (UCB, SLE), gantenerumab (Roche; Alzheimer’s disease), gevokizumab (Xoma/Servier, Non-infectious uveitis), itolizumab (Biocon, Plaque psoriasis), ixekizumab (Eli Lilly and Co., psoriasis), lebrikizumab (Roche/Genentech, rheumatoid arthritis), mepolizumab (GSK, Asthma, COPD etc.), ocrelizumab (Roche/Genentech, multiple sclerosis), reslizumab (Teva, Eosinophilic asthma), romosozumab (Amgen, Postmenopausal osteoporosis), sarilumab (Regeneron; Sanofi, rheumatoid arthritis), secukinumab (Novartis, rheuma, psoriasis), sirukumab (Janssen R&D LLC, rheumatoid arthritis), solanezumab (Eli Lilly and Co., Alzheimer’s disease), tabalumab (Eli Lilly and Co., rheuma, SLE) and vedolizumab (Millenium, Ulcerative colitis; Crohn disease). The mixture of actoxumab and bezlotoxumab (MK-3415A, Merck & Co.) is being evaluated in two Phase 3 studies as a treatment for Clostridium difficile infection.  

The ten cancer mAbs are: elotuzumab (Bristol-Myers Squibb, Abbott, multiple myeloma), farletuzumab (Morphotek, ovarian cancer), inotuzumab ozogamicin (Pfizer; UCB, ALL, NHL), naptumomab estafenatox (Active Biotech, renal cell carcinoma), necitumumab (ImClone LLC, NSCL), nivolumab (Bristol-Myers Squibb, NSCL, renal cell carcinoma), obinutuzumab (Roche/Genetech, Diffuse large B cell lymphoma, CLL, NHL), onartuzumab (Roche/Genetech, NSCL cancer; gastric cancer), racotumomab (CIMAB; Laboratorio Elea S.A.C.I.F. y A, NSCL), and ramucirumab (ImClone LLC, Gastric; liver, breast, colorectal, NSCL cancers).

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/biologics-to-watch-in-2013.html

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE4.64 EUR7.16%
  • FORMYCON16.89 EUR4.07%
  • BIOFRONTERA1.99 EUR3.65%

FLOP

  • HBM102.00 CHF-2.86%
  • SYNGENTA327.00 CHF-2.15%
  • STRATEC BIOMEDICAL45.12 EUR-2.10%

TOP

  • WILEX3.17 EUR47.4%
  • EVOLVA1.70 CHF18.9%
  • MEDIGENE4.64 EUR16.0%

FLOP

  • MOLOGEN5.25 EUR-12.5%
  • SANTHERA98.45 CHF-10.2%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA98.45 CHF2417.9%
  • WILEX3.17 EUR395.3%
  • FORMYCON16.89 EUR119.4%

FLOP

  • CYTOS0.37 CHF-86.9%
  • MOLOGEN5.25 EUR-56.0%
  • PAION2.10 EUR-52.5%

No liability assumed, Date: 03.03.2015